Effects of two different immunotherapies on triple negative breast cancer in animal model

The ability of immune system to react specifically against tumors inspirited the study of triple negative breast cancer (TNBC) immunotherapies. Sixty spontaneous breast cancer TA2 mice were randomly divided into three groups: GM-CSF group, with therapy of granulocyte–macrophage colony-stimulating factor (GM-CSF) combined with breast cancer stem cells associated antigens and cytosine–phosphorothioate–guanine oligodeoxynucleotides (CpG-ODNs); DC–CIK group, with infusions of dendritic cells/cytokine-induced killer (DC/CIK) cells; and PBS group as controls. After therapy, the cellular immunity of mice in GM-CSF group and DC–CIK group was obviously increased, especially for GM-CSF group (P < 0.05), tumor regression was obviously observed in GM-CSF group. The survival rate of mice in GM-CSF group was significantly higher compared to DC–CIK group and PBS group. These results indicated that tumor immunotherapy manifested strong killing activity against TNBC. The therapeutic effect of GM-CSF combined with antigens and CpG was better than DC–CIK cells.